Transaction · 0001628280-26-058008

Welgus Howard G.

Welgus Howard G., DIR, reported a transaction classified as exercise at Arcutis Biotherapeutics, Inc. involving 2255.000000 shares for an estimated $19460.65. Reported holdings after the transaction were 41205.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MDIR
ARQTArcutis Biotherapeutics, Inc.
Filing timeAug 19
Trade dateAug 17, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$26.46
Pre-filing
1mo ago +7.7%1w ago -2.0%1d ago -1.0%
Returns since
7d -5.0%30d -10.2%90d -10.2%180d -10.2%1y -10.2%

ARQT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ARQT since 2026-08-19Filed 15 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001628280-26-058008
Common Stock
Transaction date
Aug 17, 2026
Filed Aug 19, 2026, 08:57 PM · 2d delay
Shares
2.25k sh
$863 per share
Estimated value
$1.94M
Computed from shares × price
Holdings after
41.2k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

  2. F2

    The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.10 to $26.25 inclusive. The Reporting Person hereby undertakes…

  3. F3

    The option is fully vested.

Original filing · 0001628280-26-058008
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ARQT